FOSCHI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.203
EU - Europa 788
AS - Asia 189
AF - Africa 2
Totale 2.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.200
SE - Svezia 158
PL - Polonia 136
IE - Irlanda 133
UA - Ucraina 108
HK - Hong Kong 97
IT - Italia 65
DE - Germania 60
RU - Federazione Russa 46
CN - Cina 40
FI - Finlandia 37
SG - Singapore 24
GB - Regno Unito 20
CH - Svizzera 15
TR - Turchia 12
FR - Francia 8
JO - Giordania 8
IN - India 4
CA - Canada 3
BE - Belgio 2
KR - Corea 2
VN - Vietnam 2
KE - Kenya 1
MU - Mauritius 1
Totale 2.182
Salva come PNG Salva come JPEG
Città #
Jacksonville 156
Fairfield 140
Warsaw 136
Chandler 135
Dublin 133
Cambridge 75
Woodbridge 75
Ashburn 68
Seattle 65
Hong Kong 64
Houston 50
Wilmington 46
Princeton 37
Ann Arbor 33
Boardman 32
Buffalo 32
Boston 29
Beijing 19
Bern 14
Singapore 14
Medford 13
Shanghai 12
Altamura 10
Norwalk 10
Lawrence 9
Izmir 8
New York 8
San Diego 8
Dearborn 7
Milan 7
Frankfurt Am Main 5
Auburn Hills 3
Bremen 3
Falls Church 3
Hillsboro 3
Kent 3
Los Angeles 3
Pune 3
Verona 3
Andover 2
Bra 2
Brussels 2
Dong Ket 2
Florence 2
Hanover 2
Kunming 2
Nanjing 2
Salerno 2
Toronto 2
West Jordan 2
Ashford 1
Bagno a Ripoli 1
Bari 1
Brescia 1
Guangzhou 1
Old Bridge 1
Ottawa 1
Phoenix 1
Redmond 1
San Mateo 1
San Severino Marche 1
Valverde 1
Washington 1
Wollerau 1
Zhengzhou 1
Totale 1.511
Salva come PNG Salva come JPEG
Nome #
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 241
Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. 103
Torasemide in the treatment of patients with cirrhosis and ascites. 92
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. 84
Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. 83
Infection of peripheral mononuclear blood cells by hepatitis C virus 82
Pathogenesis and treatment of ascites in hepatic cirrhosis. 79
Loop diuretic therapy in liver cirrhosis with ascites 78
Respiratory mechanics in patients with tense cirrhotic ascites. 76
Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis. 73
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. 72
Vascular reserve in the lower limbs of cirrhotic patients: a duplex Doppler ultrasound study. 69
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 69
Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. 64
Gestione avanzata dell’ictus ischemico acuto. Due anni di attività dello Stroke Team dell’Ospedale di Careggi, Firenze. 64
Renal impairement in chronic liver diseases with and without cholestasis 61
Continuous recording of dicrotic and pulse pressures during head-up tilting test: the vasodepressive profile. Preliminary data. 54
Acetaldehyde inhibits peroxisome proliferator-activated receptor gamma (PPARg) transcriptional activity in hepatic stellate cells. A MAPk/pkcdelta-dependent mechanism. 52
Cerebral autoregulation in patients with cirrhosis and ascites. A transcranial Doppler study. 50
Le epatiti croniche 48
Baroreflex function in vasodepressive syncope: detection of early impairment.Med Sci Monit. 2003 Mar;9(3):CR125-30. 46
Effects of recombinant human gamma-interferon on advanced hepatocellular carcinoma 42
EFFECTS OF RECOMBINANT HUMAN GAMMA-INTERFERON ON ADVANCED HEPATOCELLULAR CARCINOMA 42
Treatment of chronic HCV hepatitis by reconbimant human interferon alpha: preliminary report of an in progress study 41
Different effects of atrial and C-type natriuretic peptide on the renal release of endothelin-1 in man 41
Therapy of chronic active hepatitis C with alfa interferon: effectiveness and prognostic factors 39
TREATMENT OF CHRONIC HCV HEPATITIS BY RECOMBINANT HUMAN INTERFERON ALPHA:PRELIMINARY REPORT OF AN IN PROGRESS STUDY 36
Epatite da virus C e terapia interferonica 36
Refractory ascites: definition, pathogenesis and treatment. 35
THERAPY OF CHRONIC ACTIVE HEPATITIS C WITH ALFA INTERFERON:EFFECTINEVESS AND PROGNOSTIC FACTORS 34
Terapia interferonica dell'epatite cronica attiva HCV-correlata con e senza cirrosi 34
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 34
Il Fegato: Fisiopatologia, Clinica, Terapia 33
Renal Impairment In Chronic Liver-Diseases With And Without Cholestasis. 32
Recenti dati sulle epatiti virali acute e croniche 28
Role of HCV and HBV infection in alcoholic liver disease: HCV RT (reverse transcriptase) PCR (polymerase chain reaction ) and HBV PCR analysis 21
Therapy Of Chronic Active Hepatitis-C With Alpha-Interferon - Effectiveness And Prognostic Factors 20
Totale 2.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.515
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.515
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020390 0 40 11 42 34 55 48 58 32 18 44 8
2020/2021303 25 11 33 30 7 54 3 31 20 43 19 27
2021/2022216 3 26 8 10 5 6 5 10 10 5 67 61
2022/2023552 53 46 33 38 52 121 74 31 61 5 21 17
2023/2024234 11 25 38 10 14 23 3 78 11 7 7 7
2024/202568 42 26 0 0 0 0 0 0 0 0 0 0
Totale 2.188